

Prof. İMRAN VURAL

Personal Information

Office Phone: [+90 312 305 1241](tel:+903123051241)

Email: imran@hacettepe.edu.tr

Education Information

Doctorate, Northeastern University, Pharmacy/Health Sciences/Pharmaceutical-Drug Targeting, United States Of America 1993 - 1998

Postgraduate, Hacettepe Üniversitesi, Eczacılık/Sağlık Bilimleri/Farmasötik Teknoloji, Turkey 1986 - 1989

Undergraduate, Hacettepe Üniversitesi, Eczacılık Fakültesi, Turkey 1982 - 1986

Foreign Languages

English, C1 Advanced

Research Areas

Health Sciences, Pharmacology and Therapeutics, Pharmaceutics Technology, Pharmaceutical Technology

Academic Titles / Tasks

Professor, Hacettepe Üniversitesi, Eczacılık Fakültesi, Eczacılık Teknolojisi Bölümü, 2012 - Continues

Associate Professor, Hacettepe Üniversitesi, Eczacılık Fakültesi, Eczacılık Teknolojisi Bölümü, 2006 - 2012

Assistant Professor, Hacettepe Üniversitesi, Eczacılık Fakültesi, Eczacılık Teknolojisi Bölümü, 2000 - 2006

Research Assistant, Hacettepe Üniversitesi, Eczacılık Fakültesi, Eczacılık Teknolojisi Bölümü, 1998 - 2000

Research Assistant, Northeastern University, Bouve College Of Pharmacy, Pharmaceutical Sciences, 1993 - 1998

Research Assistant, Hacettepe Üniversitesi, Eczacılık Fakültesi, Eczacılık Teknolojisi Bölümü, 1986 - 1992

Academic and Administrative Experience

Hacettepe Üniversitesi, Eczacılık Fakültesi, Eczacılık Teknolojisi Bölümü, 2016 - 2018

Courses

Farmasötik Teknoloji III LabErzincan Üniversitesi, Undergraduate, 2016 - 2017

Farmasötik Teknoloji III Erzincan Üniversitesi, Undergraduate, 2016 - 2017

FARMASÖTİK TEKNOLOJİ III, Undergraduate, 2016 - 2017

NNT-NANOTEKNOLOJİ İLAÇ HEDEFLENDİRİLMESİ, Doctorate, 2016 - 2017

Farmasötik Teknoloji II Lab -Erzincan Üniversitesi, Undergraduate, 2016 - 2017

FARMASÖTİK TEKNOLOJİ II, Undergraduate, 2016 - 2017

Farmasötik Teknoloji IV Lab-Erzincan Üniversitesi, Undergraduate, 2016 - 2017

Farmsötik Teknoloji IV -Erzincan Üniversitesi, Undergraduate, 2016 - 2017
FARMASÖTİK TEKNOLOJİ İLAB-ERZİNCAN ÜNİVERSİTESİ, Undergraduate, 2016 - 2017
FARMASÖTİK TEKNOLOJİ I, Undergraduate, 2016 - 2017
FARMASÖTİK TEKNOLOJİ I-ERZİNCAN ÜNİVERSİTESİ, Undergraduate, 2016 - 2017
YENİ İLAÇ TAŞIYICI SİSTEMLER, Postgraduate, 2016 - 2017
FARMASÖTİK TEKNOLOJİ I LAB, Undergraduate, 2016 - 2017

Advising Theses

VURAL İ., Fosinopril sodyum içeren ağızda hızla dağılan dozaj formlarının geliştirilmesi ve karakterizasyonları, Postgraduate, G.ŞAHİN(Student), 2016
VURAL İ., Kanser tedavisinde kullanılacak aktif hedeflendirilmiş farmasötik nanotaşıyıcılar, Doctorate, C.SARISÖZEN(Student), 2012
VURAL İ., Development of rapamycin drug delivery systems, their characterization and investigation of the antiproliferative effect on cell cultures, Doctorate, M.ABDUR(Student), 2007

Articles Published in Journals That Entered SCI, SSCI and AHCI Indexes

- I. **Poly(2-ethyl-2-oxazoline-co-ethyleneimine)-block-poly(epsilon-caprolactone) based micelles: synthesis, characterization, peptide conjugation and cytotoxic activity**
Gulyuz S., Ozkose U. U. , Khalily M. P. , KESİCİ M. S. , Kocak P., Bolat Z. B. , KARA A., ÖZTÜRK N., ÖZÇUBUKÇU S., BOZKIR A., et al.
NEW JOURNAL OF CHEMISTRY, vol.45, pp.14532-14547, 2021 (Journal Indexed in SCI)
- II. **Development and characterization of pullulan-based orally disintegrating films containing amlodipine besylate**
PEZİK E., Gulsun T., ŞAHİN S., VURAL İ.
European Journal of Pharmaceutical Sciences, vol.156, 2021 (Journal Indexed in SCI)
- III. **Exploiting ionisable nature of PEtOx-co-PEI to prepare pH sensitive, doxorubicin-loaded micelles**
ÖZTÜRK N., KARA A., Gulyuz S., Ozkose U. U. , TAŞDELEN M. A. , BOZKIR A., Yılmaz O., VURAL İ.
JOURNAL OF MICROENCAPSULATION, vol.37, no.7, pp.467-480, 2020 (Journal Indexed in SCI)
- IV. **Design of ocular drug delivery platforms and in vitro - in vivo evaluation of riboflavin to the cornea by non-interventional (epi-on) technique for keratoconus treatment**
AYTEKİN E., ÖZTÜRK N., Vurla İ., POLAT H. K. , Çakmak H. B. , ÇALIŞ S., Pehlivan S. B.
Journal of Controlled Release, vol.324, pp.238-249, 2020 (Journal Indexed in SCI Expanded)
- V. **Development of an Anti-Inflammatory Drug-Incorporated Biomimetic Scaffold for Corneal Tissue Engineering**
Celebier S. K. , Pehlivan S., DEMİRBİLEK M., Akinci M., VURAL İ., AKDAĞ ÇAYLI Y., Yuruker S., Unlu N.
Journal of Ocular Pharmacology and Therapeutics, vol.36, no.6, pp.433-446, 2020 (Journal Indexed in SCI Expanded)
- VI. **Combination of Paclitaxel and R-flurbiprofen loaded PLGA nanoparticles suppresses glioblastoma growth on systemic administration**
Caban-Toktas S., Sahin A., Lule S., Esendagli G., Vural İ., Karlı Oguz K., Soylemezoglu F., Mut M., Dalkara T., Khan M., et al.
International Journal of Pharmaceutics, vol.578, 2020 (Journal Indexed in SCI)
- VII. **Preparation, characterization and pharmacokinetic evaluation of rosuvastatin calcium incorporated cyclodextrin-polyanhydride nanoparticles**
Al-Heibshy F. N. S. , BAŞARAN E., ARSLAN R., ÖZTÜRK N., VURAL İ., DEMİREL M.
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, vol.45, no.10, pp.1635-1645, 2019 (Journal Indexed in SCI)
- VIII. **Floating drug delivery system of itraconazole: Formulation, in vitro and in vivo studies**

Gokbulut E., VURAL İ., Asikoglu M., Ozdemir N.

JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, vol.49, pp.491-501, 2019 (Journal Indexed in SCI)

- IX. **Preparation and characterization of furosemide nanosuspensions**
GÜLSÜN İNAL T., Borna S. E. , VURAL İ., ŞAHİN S.
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, vol.45, pp.93-100, 2018 (Journal Indexed in SCI)
- X. **Development and characterization of gels and liposomes containing ovalbumin for nasal delivery**
Kaplan M., Tugcu-Demiroz F., VURAL İ., Celebi N.
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, vol.44, pp.108-117, 2018 (Journal Indexed in SCI)
- XI. **Development and evaluation of orally disintegrating tablets comprising taste-masked mirtazapine granules**
Yildiz S., AYTEKİN E., Yavuz B., Pehlivan S. B. , VURAL İ., UNLU N.
PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, vol.23, no.5, pp.488-495, 2018 (Journal Indexed in SCI)
- XII. **Development of novel self-assembled polymeric micelles from partially hydrolysed poly(2-ethyl-2-oxazoline)-co-PEI-b-PCL block copolymer as non-viral vectors for plasmid DNA in vitro transfection**
Kara A., Ozturk N., ESENDAĞLI G., Ozkose U. U. , Gulyuz S., Yilmaz O., Telci D., Bozkir A., VURAL İ.
ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY, vol.46, 2018 (Journal Indexed in SCI)
- XIII. **A potential non-invasive glioblastoma treatment: Nose-to-brain delivery of farnesylthiosalicylic acid incorporated hybrid nanoparticles**
SEKERDAG E., Lule S., PEHLIVAN S. B. , Ozturk N., KARA A., KAFFASHI A., VURAL İ., Isikay I., Yavuz B., OGUZH K. K. , et al.
JOURNAL OF CONTROLLED RELEASE, vol.261, pp.187-198, 2017 (Journal Indexed in SCI)
- XIV. **Farnesylthiosalicylic acid-loaded lipid-polyethylene glycol-polymer hybrid nanoparticles for treatment of glioblastoma**
KAFFASHI A., Lule S., PEHLIVAN S. B. , SARISOZEN C., VURAL İ., KOSUCU H., Demir T., Bugdayci K. E. , Soylemezoglu F., OGUZ K. K. , et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY, vol.69, no.8, pp.1010-1021, 2017 (Journal Indexed in SCI)
- XV. **Dry powders for the inhalation of ciprofloxacin or levofloxacin combined with a mucolytic agent for cystic fibrosis patients.**
Akdag C., SAHIN S., BUTTINI F., BALDUCCI A., MONTANARI S., VURAL I., ONER L.
Drug development and industrial pharmacy, vol.43, pp.1378-1389, 2017 (Journal Indexed in SCI Expanded)
- XVI. **Preparation and evaluation of furosemide containing orally disintegrating tablets by direct compression**
Gulsun T., Ozturk N., Kaynak M. S. , Vural I., Sahin S.
PHARMAZIE, vol.72, no.7, pp.389-394, 2017 (Journal Indexed in SCI)
- XVII. **New azole derivatives showing antimicrobial effects and their mechanism of antifungal activity by molecular modeling studies**
DOGAN I. S. , SARAC S., SARI S., KART D., Gokhan S. E. , VURAL İ., DALKARA S.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol.130, pp.124-138, 2017 (Journal Indexed in SCI)
- XVIII. **Design and In Vitro Evaluation of Bispecific Complexes and Drug Conjugates of Anticancer Peptide, LyP-I in Human Breast Cancer**
TİMUR S. S. , Bhattarai P., GÜRİSOY R. N. , VURAL İ., Khaw B.
PHARMACEUTICAL RESEARCH, vol.34, no.2, pp.352-364, 2017 (Journal Indexed in SCI)
- XIX. **In Vitro CNS Models**
KARA A., ÖZTÜRK N., VURAL İ.
NANOTECHNOLOGY METHODS FOR NEUROLOGICAL DISEASES AND BRAIN TUMORS: DRUG DELIVERY ACROSS THE BLOOD-BRAIN BARRIER, pp.151-185, 2017 (Journal Indexed in SCI)
- XX. **Evaluation of Antitumor Activity of a Non-Steroidal Anti-Inflammatory Drug, Ibuprofen, by a Targeted Nanoparticulate System**
ÖZTÜRK N., KARA A., VURAL İ.
LATIN AMERICAN JOURNAL OF PHARMACY, vol.36, no.1, pp.44-52, 2017 (Journal Indexed in SCI)
- XXI. **Dexamethasone - PAMAM dendrimer conjugates for retinal delivery: preparation, characterization**

and in vivo evaluation

Yavuz B., Pehlivan S., Bolu B. S. , Sanyal R. N. , VURAL İ., UNLU N.

JOURNAL OF PHARMACY AND PHARMACOLOGY, vol.68, no.8, pp.1010-1020, 2016 (Journal Indexed in SCI)

- XXII. **Lysozyme-loaded lipid-polymer hybrid nanoparticles: preparation, characterization and colloidal stability evaluation**
DEVİRİM B., KARA A., VURAL İ., Bozkiir A.
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, vol.42, no.11, pp.1865-1876, 2016 (Journal Indexed in SCI)
- XXIII. **In Vitro/In Vivo Evaluation of Dexamethasone PAMAM Dendrimer Complexes for Retinal Drug Delivery**
Yavuz B., Pehlivan S., VURAL İ., UNLU N.
JOURNAL OF PHARMACEUTICAL SCIENCES, vol.104, no.11, pp.3814-3823, 2015 (Journal Indexed in SCI)
- XXIV. **Preparation and in vitro/in vivo evaluation of cyclosporin A-loaded nanodecorated ocular implants for subconjunctival application**
PEHLIVAN S., Yavuz B., ÇALAMAK S., ULUBAYRAM K., KAFFASHI A., VURAL İ., Cakmak H. B. , DURGUN M. E. , DENKBAŞ E. B. , UNLU N.
Journal of Pharmaceutical Sciences, vol.104, no.5, pp.1709-1720, 2015 (Journal Indexed in SCI Expanded)
- XXV. **5-Fluorouracil-loaded PLA/PLGA PEG-PPG-PEG polymeric nanoparticles: formulation, in vitro characterization and cell culture studies**
Ocal H., Arica-Yegin B., VURAL İ., Goracinova K., ÇALIŞ S.
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, vol.40, no.4, pp.560-567, 2014 (Journal Indexed in SCI)
- XXVI. **Development and Evaluation of Paclitaxel Nanoparticles Using a Quality-by-Design Approach**
Yerlikaya F., Ozgen A., VURAL İ., Guven O., Karaagaoglu E., Khan M. A. , ÇAPAN Y.
JOURNAL OF PHARMACEUTICAL SCIENCES, vol.102, no.10, pp.3748-3761, 2013 (Journal Indexed in SCI)
- XXVII. **Preparation and characterization of metformin hydrochloride loaded-Eudragit (R) RSPO and Eudragit (R) RSPO/PLGA nanoparticles**
ÇETİN M., ATİLA A., ŞAHİN S., VURAL İ.
PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, vol.18, no.3, pp.570-576, 2013 (Journal Indexed in SCI)
- XXVIII. **Preparation and characterization of nimesulide containing nanocrystal formulations**
Gulsun T., Budak C., VURAL İ., ŞAHİN S., ÖNER L.
PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, vol.18, no.3, pp.653-659, 2013 (Journal Indexed in SCI)
- XXIX. **In vitro studies on 5-fluorouracil-loaded DTPA-PE containing nanosized pegylated liposomes for diagnosis and treatment of tumor**
Liko F., ERDOĞAN S., Ozer Y. A. , VURAL İ.
JOURNAL OF LIPOSOME RESEARCH, vol.23, no.1, pp.61-69, 2013 (Journal Indexed in SCI)
- XXX. **Formulation and evaluation of clozapine orally disintegrating tablets prepared by direct compression**
OLMEZ S. S. , VURAL İ., ŞAHİN S., ERTUĞRUL A., ÇAPAN Y.
PHARMAZIE, vol.68, no.2, pp.110-116, 2013 (Journal Indexed in SCI)
- XXXI. **Long-circulating PEG-PE micelles co-loaded with paclitaxel and elacridar (GG918) overcome multidrug resistance**
Sarisozen C., VURAL İ., Levchenko T., Hincal A. A. , Torchilin V. P.
DRUG DELIVERY, vol.19, no.8, pp.363-370, 2012 (Journal Indexed in SCI)
- XXXII. **Reversal of multidrug resistance by antibody targeted micelles**
Sarisozen C., VURAL İ., Hincal A. A. , Torchilin V. P.
NEW BIOTECHNOLOGY, vol.29, 2012 (Journal Indexed in SCI)
- XXXIII. **PEG-PE-based micelles co-loaded with paclitaxel and cyclosporine A or loaded with paclitaxel and targeted by anticancer antibody overcome drug resistance in cancer cells**
Sarisozen C., VURAL İ., Levchenko T., Hincal A. A. , Torchilin V. P.
DRUG DELIVERY, vol.19, no.4, pp.169-176, 2012 (Journal Indexed in SCI)
- XXXIV. **Both mitogen-activated protein kinase (MAPK)/extracellular-signal-regulated kinases (ERK) 1/2 and phosphatidylinositolide-3-OH kinase (PI3K)/Akt pathways regulate activation of E-twenty-six (ETS)-**

like transcription factor 1 (Elk-1) in U138 glioblastoma cells

Mut M., Lule S., Demir O., Kurnaz I. A. , VURAL İ.

International Journal of Biochemistry and Cell Biology, vol.44, no.2, pp.302-310, 2012 (Journal Indexed in SCI Expanded)

- XXXV. **Salmon calcitonin-loaded Eudragit (R) and Eudragit (R)-PLGA nanoparticles: in vitro and in vivo evaluation**
ÇETİN M., AKTAŞ M. S. , VURAL İ., Ozturk M.
JOURNAL OF MICROENCAPSULATION, vol.29, no.2, pp.156-166, 2012 (Journal Indexed in SCI)
- XXXVI. **CHARACTERIZATION, CELL PROLIFERATION AND CYTOTOXICITY EVALUATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR LOADED POLY (LACTIC-CO-GLYCOLIC ACID) MICROSPHERES**
KERİMOĞLU O., ALARÇİN E., Turkoglu M., Dortunc B., Karagoz H., Ulkur E., VURAL İ., ÇAPAN Y.
NOBEL MEDICUS, vol.8, no.1, pp.77-82, 2012 (Journal Indexed in SCI)
- XXXVII. **Rosuvastatin induces apoptosis in cultured human papillary thyroid cancer cells**
ZEYBEK N. D. , Gulcelik N. E. , KAYMAZ F. F. , Sarisozen C., VURAL İ., BODUR E., CANPINAR H., Usman A., Asan E.
JOURNAL OF ENDOCRINOLOGY, vol.210, no.1, pp.105-115, 2011 (Journal Indexed in SCI)
- XXXVIII. **Chitosan Coated Furosemide Liposomes for Improved Bioavailability**
VURAL İ., Sarisozen C., Olmez S. S.
JOURNAL OF BIOMEDICAL NANOTECHNOLOGY, vol.7, no.3, pp.426-430, 2011 (Journal Indexed in SCI)
- XXXIX. **Rapamycin-cyclodextrin complexation: Improved solubility and dissolution rate**
Abdur Rouf M., VURAL İ., BİLENSOY E., Hincal A., Erol D. D.
Journal of Inclusion Phenomena and Macrocyclic Chemistry, vol.70, pp.167-175, 2011 (Journal Indexed in SCI)
- XL. **Evaluation of drug-excipient interaction in the formulation of celecoxib tablets**
Bozdog-Pehlivan S., Subasi B., VURAL İ., Unlu N., ÇAPAN Y.
Acta Poloniae Pharmaceutica - Drug Research, vol.68, no.3, pp.423-433, 2011 (Journal Indexed in SCI Expanded)
- XLI. **An alternative cyclodextrin based formulation for oral anticancer drug exemestane: In vitro and cell culture studies.**
Yavuz B., Sarisozen C., Vural İ., Bilensoy E., Sumnu M.
Journal of controlled release : official journal of the Controlled Release Society, vol.148, no.1, 2010 (Journal Indexed in SCI)
- XLII. **Alternative oral exemestane formulation: Improved dissolution and permeation**
Yavuz B., BİLENSOY E., VURAL İ., Sumnu M.
INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol.398, pp.137-145, 2010 (Journal Indexed in SCI)
- XLIII. **Preparation and characterization of anticancer drug-loaded implantable PLGA microparticles**
ÇETİN M., VURAL İ., ATİLA A., KADIOĞLU Y.
TURKISH JOURNAL OF CHEMISTRY, vol.34, no.4, pp.509-516, 2010 (Journal Indexed in SCI)
- XLIV. **Development and characterization of liposomal formulations for rapamycin delivery and investigation of their antiproliferative effect on MCF7 cells**
Rouf M. A. , VURAL İ., Renoir J. M. , Hincal A. A.
JOURNAL OF LIPOSOME RESEARCH, vol.19, no.4, pp.322-331, 2009 (Journal Indexed in SCI)
- XLV. **FORMULATION AND IN VITRO EVALUATION OF EUDRAGIT-L100/PLGA NANOPARTICLES CONTAINING SALMON CALCITONIN**
ÇETİN M., VURAL İ., ATİLA A., Sarisozen C., KADIOĞLU Y.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol.38, no.1, pp.85-86, 2009 (Journal Indexed in SCI)
- XLVI. **DEVELOPMENT AND CHARACTERIZATION OF THEOPHYLLINE LOADED PLGA MICROSPHERES**
Shamil D., Sarisozen C., Pehlivan S. B. , Basit A., ŞAHİN S., VURAL İ.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol.38, no.1, pp.96-97, 2009 (Journal Indexed in SCI)
- XLVII. **CHITOSAN COATED LIPOSOMES LOADED WITH FUROSEMIDE: CHARACTERIZATION AND CELLULAR INTERACTION**
Sarisozen C., Olmez S. S. , VURAL İ.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol.38, no.1, pp.82-83, 2009 (Journal Indexed in SCI)
- XLVIII. **PEG-PE BASED MIXED MICELLES LOADED WITH PACLITAXEL FOR ANTITUMOR ACTIVITY:**

ENHANCED DRUG SOLUBILIZATION

Sarisozen C., VURAL İ., Torchilin V. P. , Hincal A. A.

EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol.38, no.1, pp.83-84, 2009 (Journal Indexed in SCI)

XLIX. PREPARATION OF FAMOTIDINE ORALLY DISINTEGRATING TABLETS

Olmez S. S. , VURAL İ.

EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol.38, no.1, pp.65-66, 2009 (Journal Indexed in SCI)

L. Microbiological and clinical comparison of chlorhexidine buccoadhesive tablet and chlorhexidine mouthrinse

AKTAŞ A., GIRAY B., ÇAPAN Y., MENEMENLIOĞLU D., HAYRAN M., İKİNCİ G., VURAL İ.

JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, vol.19, no.5, pp.353-357, 2009 (Journal Indexed in SCI)

L.I. Hyaluronic acid coated poly-ε-caprolactone nanospheres deliver high concentrations of cyclosporine A into the cornea

Yenice I., Mocan M. C. , PALASKA E., Bochot A., BİLENSOY E., VURAL İ., Irkeç M., Atilla Hincal A.

Experimental Eye Research, vol.87, no.3, pp.162-167, 2008 (Journal Indexed in SCI)

L.II. Preparation and in vitro evaluation of bFGF-loaded chitosan nanoparticles

Cetin M., Aktas Y., Vural İ., Capan Y., Dogan L. A. , Duman M., Dalkara T.

DRUG DELIVERY, vol.14, no.8, pp.525-529, 2007 (Journal Indexed in SCI)

L.III. Treatment of malignant gliomas with mitoxantrone-loaded poly (lactide-co-glycolide) microspheres

Yemisci M., Vural İ., Bozdag S., Cetin M., Soylemezoglu F., Capan Y., Dalkara T.

Neurosurgery, vol.59, no.6, pp.1296-1302, 2006 (Journal Indexed in SCI Expanded)

L.IV. Mucoadhesive, thermosensitive, prolonged-release vaginal gel for clotrimazole: β-cyclodextrin complex

Bilensoy E., Rouf M. A. , Vural İ., Sen M., Hincal A. A.

AAPS PharmSciTech, vol.7, no.2, 2006 (Journal Indexed in SCI)

L.V. Thermosensitive vaginal gel formulation for the controlled release of clotrimazole via complexation to beta-cyclodextrin.

BİLENSOY E., Rouf M., VURAL İ., Hincal A.

Journal of controlled release : official journal of the Controlled Release Society, vol.116, no.2, 2006 (Journal Indexed in SCI)

L.VI. Preparation and characterization of PLGA nanospheres for the targeted delivery of NR2B-specific antisense oligonucleotides to the NMDA receptors in the brain

KİLİC A. C. , Capan Y., Vural I., GURSOY R. N. , Dalkara T., CUİNE A., HİNCAL A. A.

JOURNAL OF MICROENCAPSULATION, vol.22, no.6, pp.633-641, 2005 (Journal Indexed in SCI)

L.VII. Preparation and characterization of bFGF and BSA-loaded microspheres

Cetin M., Capan Y., Vural I., Dogan A., Guc D., Hincal A., Wehrle P., Dalkara T.

JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, vol.15, no.5, pp.371-375, 2005 (Journal Indexed in SCI)

L.VIII. Transcription efficiency of tamoxifen citrate-loaded beta-cyclodextrin nanoparticles

Vural I., Memisoglu-Bilensoy E., Renoir J., Bochot A., Duchene D., Hincal A.

JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, vol.15, no.5, pp.339-342, 2005 (Journal Indexed in SCI)

L.IX. Tamoxifen citrate loaded amphiphilic β-cyclodextrin nanoparticles: In vitro characterization and cytotoxicity

Memisoglu-Bilensoy E., VURAL İ., Bochot A., Renoir J. M. , Duchene D., Hincal A. A.

Journal of Controlled Release, vol.104, no.3, pp.489-496, 2005 (Journal Indexed in SCI)

LX. Formulation and in vitro bioactivity of mitoxantrone-loaded biodegradable microspheres on rat glioma (RG2) cells

Bozdag S., Capan B., Vural I., Dalkara T., Dogan A., Guc D., Hincal A., DeLuca P.

Journal of Drug Delivery Science and Technology, vol.15, no.3, pp.201-206, 2005 (Journal Indexed in SCI Expanded)

- LXI. **Transcription efficiency of tamoxifen citrate-loaded β -cyclodextrin nanoparticles**
VURAL İ., Memisoglu-Bilensoy E., Renoir J., Bochot A., Duchêne D., Hincal A.
Journal of Drug Delivery Science and Technology, vol.15, no.5, pp.339-342, 2005 (Journal Indexed in SCI Expanded)
- LXII. **In vitro cytotoxicity of mitoxantrone-incorporated albumin microspheres on acute promyelocytic leukaemia cells**
Bozdog S., Capan Y., Vural I., Dalkara T., Dogan A., Guc D., Hincal A., Deluca P.
Journal of Microencapsulation, vol.21, no.7, pp.751-760, 2004 (Journal Indexed in SCI Expanded)
- LXIII. **Mitoxantrone loaded poly(DL-lactide-co-glycolide) microspheres for treatment of brain tumors I. formulation and release characteristics**
Bozdağ S., ÇAPAN Y., VURAL İ., Hincal A., DeLuca P.
Technology and Health Care, vol.10, pp.353-355, 2002 (Journal Indexed in SCI Expanded)
- LXIV. **Intracytoplasmic gene delivery for in vitro transfection with cytoskeleton-specific immunoliposomes**
Khaw B., da Silva J., Vural İ., Narula J., Torchilin V.
JOURNAL OF CONTROLLED RELEASE, vol.75, pp.199-210, 2001 (Journal Indexed in SCI)
- LXV. **Use of cytoskeleton-specific immunoliposomes for preservation of cell viability and gene delivery**
Khaw B., Vural İ., DaSilva J., Torchilin V.
S.T.P. Pharma Sciences, vol.10, no.4, pp.279-283, 2000 (Journal Indexed in SCI)
- LXVI. **PLUG AND SEAL - PREVENTION OF HYPOXIC CARDIOCYTE DEATH BY SEALING MEMBRANE LESIONS WITH ANTIMYOSIN-LIPOSOMES**
KHAW B., TORCHILIN V., VURAL İ., NARULA J.
NATURE MEDICINE, vol.1, no.11, pp.1195-1198, 1995 (Journal Indexed in SCI)
- LXVII. **EFFECT OF ENCAPSULATION OF CHLORAMPHENICOL IN ALBUMIN MICROSPHERES ON ITS IN-VITRO TRANSFER ACROSS THE HUMAN PLACENTA**
ONUR M., VURAL İ., BASCI N. E. , PAMIR R., COSKUN T., ISIMER A., KAS H., BEKSAC S., HINCAL A., TUMER A.
JOURNAL OF MICROENCAPSULATION, vol.11, no.6, pp.657-662, 1994 (Journal Indexed in SCI)
- LXVIII. **Cyclophosphamide loaded albumin microspheres. IV. Application of factorial design**
VURAL İ., Kas H., ÖNER L., Hincal A.
S.T.P. Pharma Sciences, vol.1, no.5, pp.318-320, 1991 (Journal Indexed in SCI Expanded)
- LXIX. **CYCLOPHOSPHAMIDE LOADED ALBUMIN MICROSPHERES .2. RELEASE CHARACTERISTICS**
VURAL İ., KAS H., HINCAL A., CAVE G.
JOURNAL OF MICROENCAPSULATION, vol.7, no.4, pp.511-516, 1990 (Journal Indexed in SCI)
- LXX. **CYCLOPHOSPHAMIDE LOADED ALBUMIN MICROSPHERES - LIVER ENTRAPMENT AND FATE IN MICE**
VURAL İ., KAS H., ERCAN M., HINCAL A.
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, vol.16, no.11, pp.1781-1789, 1990 (Journal Indexed in SCI)

Articles Published in Other Journals

- I. **Effect of precipitation inhibitors on supersaturation and solubility of furosemide**
GÜLSÜN İNAL T., ÖZTÜRK N., Kara A., ŞAHİN S., VURAL İ.
JOURNAL OF RESEARCH IN PHARMACY, vol.25, no.2, pp.209-217, 2021 (Journal Indexed in ESCI)
- II. **Formulation and In Vitro Evaluation of Telmisartan Nanoparticles Prepared by Emulsion-Solvent Evaporation Technique**
ÖZTÜRK N., KARA A., VURAL İ.
TURKISH JOURNAL OF PHARMACEUTICAL SCIENCES, vol.17, no.5, pp.492-499, 2020 (Journal Indexed in ESCI)
- III. **Türk Farmakopesi Hazırlık Çalışmaları ve 26-28 Ocak 2017 Çeşme Çalıştayı**
PALASKA E., VURAL İ., KOÇ F., ÖZDEMİRHAN M. E.
Türk Farmakope Dergisi, vol.2, no.1, pp.114-123, 2017 (Other Refereed National Journals)
- IV. **Gen taşınması için olası bir yaklaşım Poli 2 oksazolin tabanlı vektörler**
KARA A., VURAL İ., YILMAZ Ö., BOZKIR A.

Hacettepe University Journal of the Faculty of Pharmacy, 2014 (Other Refereed National Journals)

- V. **Formulation and in vitro evaluation of paclitaxel loaded nanoparticles Paklitaksel yüklü nanopartiküllerin formülasyonu ve in vitro incelenmesi**
Aygül G., Yerlikaya F., Caban S., VURAL İ., ÇAPAN Y.
Hacettepe University Journal of the Faculty of Pharmacy, vol.33, no.1, pp.25-40, 2013 (Refereed Journals of Other Institutions)
- VI. **Orally disintegrating tablets ii: In vitro and in vivo evaluations Ağızda dağılan tabletler ii: In vitro ve in vivo değerlendirilmeleri**
Ölmez S. S. , VURAL İ., ŞAHİN S., ERTUĞRUL A., ÇAPAN Y.
Hacettepe University Journal of the Faculty of Pharmacy, vol.31, no.1, pp.59-70, 2011 (Refereed Journals of Other Institutions)
- VII. **Orally disintegrating tablets i: Preparation technologies Ağızda dağılan tabletler i: Hazırlama teknolojileri**
Ölmez S. S. , VURAL İ., ŞAHİN S., ERTUĞRUL A., ÇAPAN Y.
Hacettepe University Journal of the Faculty of Pharmacy, vol.30, no.2, pp.205-230, 2010 (Refereed Journals of Other Institutions)
- VIII. **Advantages and quality control of orally disintegrating tablets**
Ölmez S. S. , VURAL İ.
Fabad Journal of Pharmaceutical Sciences, vol.34, no.3, pp.167-172, 2009 (Refereed Journals of Other Institutions)
- IX. **Preparation and characterization of BSA-loaded alginate microspheres**
ÇETİN M., VURAL İ., ÇAPAN Y., HİNCAL A. A.
Fabad Journal of Pharmaceutical Sciences, vol.32, no.3, pp.103-107, 2007 (Refereed Journals of Other Institutions)
- X. **Method Validation in Determination of Mitoxantrone by HPLC**
Bozdağ S., ÇAPAN Y., VURAL İ., HİNCAL A. A.
Acta Pharmaceutica Turcica, vol.46, no.1, pp.43-47, 2004 (Refereed Journals of Other Institutions)
- XI. **Comparative efficiencies of transfection by cationic liposomes and cytoskeleton specific immunoliposomes**
Khaw B., Vural İ., Narula J., Torchilin V.
Proceedings of the Controlled Release Society, no.26, pp.216-217, 1999 (Refereed Journals of Other Institutions)
- XII. **Intracytoplasmic delivery of plasmid pGL2 vector by cytoskeleton specific immunoliposome transfection**
Khaw B., Vural İ., Torchilin V., Narula J.
Proceedings of the Controlled Release Society, no.25, pp.178-179, 1998 (Refereed Journals of Other Institutions)
- XIII. **Preservation of cardiocyte viability by immunoliposome-cell membrane sealing at 1, 2, 3, 4 and 5 days of hypoxia**
Khaw B., Vural İ., Narula J., Haider N., Torchilin V.
Proceedings of the Controlled Release Society, no.23, pp.617-618, 1996 (Refereed Journals of Other Institutions)
- XIV. **Expression of antimyosin sFv gene in cardiocytes: Use of cytoskeleton-specific immunoliposomes for transfection**
Khaw B., Vural İ., Torchilin V., Haider N., Narula J.
Proceedings of the Controlled Release Society, no.23, pp.135-136, 1996 (Refereed Journals of Other Institutions)
- XV. **A method for targeted intracellular delivery of drugs and genes: A novel utilization of immunoliposomes**
Vural İ., Narula J., Torchilin V., Khaw B.
Proceedings of the Controlled Release Society, no.22, pp.450-451, 1995 (Refereed Journals of Other Institutions)
- XVI. **Targeted sealing of cell membrane lesions: Model of preservation of cell viability by immunoliposome therapy**
Khaw B., Vural İ., Narula J., Torchilin V.
Proceedings of the Controlled Release Society, no.22, pp.184-185, 1995 (Refereed Journals of Other Institutions)
- XVII. **Quantitation of specific targeting of antimyosin immuno liposomes to necrotic myoblast cells**
Vural İ., Torchilin V., Narula J., Khaw B.

Refereed Congress / Symposium Publications in Proceedings

- I. **EVALUATION OF DUAL EFFECT OF SODIUM BOROHYDRIDE (NaBH₄) AS A REDUCING AND CROSSLINKING AGENT FOR DEVELOPMENT OF SILVER NANOPARTICLES (AgNPs) LOADED CHITOSAN-POLY(VINYL ALCOHOL)(CS-PVA) HYDROGELS**
KARA A., ÖZTÜRK N., VURAL İ.
8th BBBB Conference on Pharmaceutical Sciences, 14 - 16 October 2019
- II. **Determination of Equilibrium Solubility of Lamotrigine Using UV Spectrophotometer**
Pezik E., Şahin S., Vural İ.
International Multidisciplinary Symposium on Drug Research Development (DRD 2019), Malatya, Turkey, 1 - 03 July 2019, pp.367-370
- III. **PREPARATION AND CHARACTERIZATION OF DOCETAXEL LOADED POLYMERIC MICELLES**
ÖZTÜRK N., KARA A., ÖZKÖSE U. U. , Gulyuz S., Yilmaz O., BOZKIR A., VURAL İ.
IPTS2018, 17 - 19 September 2018
- IV. **EVALUATION OF STEALTH PROPERTIES OF PEtOx BASED MICELLE/GENE COMPLEXES BY STABILITY STUDIES**
KARA A., ÖZTÜRK N., Gulyuz S., ÖZKÖSE U. U. , bolat z. b. , Yilmaz O., TELCİ D., BOZKIR A., VURAL İ.
IPTS 2018, 17 - 19 September 2018
- V. **APOPTOTIC GENE THERAPY BY NOVEL DEVELOPED PARTIALLY HYDROLYSED PEtOx BASED MICELLAR NANOCARRIERS ON MCF-7 BREAST CANCER CELLS**
KARA A., ÖZTÜRK N., ESENDAĞLI G., ÖZKÖSE U. U. , Gulyuz S., bolat z. b. , Yilmaz O., TELCİ D., BOZKIR A., VURAL İ.
IPTS2018, 17 - 19 September 2018
- VI. **Effect Of Lamotrigine On Viability Of MCF-7 And RG-2 Cells**
Pezik E., Öztürk N., Çeliker A., Şahin S., Vural İ.
19th International Pharmaceutical Technology Symposium (IPTS 2018) , Antalya, Turkey, 17 - 19 September 2018, pp.212-213
- VII. **IN VITRO EVALUATION OF pH SENSITIVE DOXORUBICIN LOADED MICELLES**
ÖZTÜRK N., KARA A., ÖZKÖSE U. U. , Gulyuz S., Yilmaz O., BOZKIR A., VURAL İ.
IPTS2018, 17 - 19 September 2018
- VIII. **Investigation of Cytotoxic Effects of Daidzein and Levetiracetam on RG2 Glioma Cell Line**
ÖZTÜRK N., UĞUR A. B. , ÇETİN M., VURAL İ.
19th International Pharmaceutical Technology Symposium, 17 - 19 September 2018, pp.176-177
- IX. **ffloating drug delivery system of itraconazole :formulation, invitro and in vivo studies**
Gökbulut E., VURAL İ., AŞIKOĞLU M., ÖZDEMİR A. N.
ISOPS 12 th international symposium on pharmaceutivcal sciences, 26 - 29 June 2018
- X. **Determination of cytotoxicity of Lamotrigine on L929 cell line.**
Pezik E., Öztürk N., Şahin S., Vural İ.
12 th International Symposium on Pharmaceutical Sciences (ISOPS 2018), Ankara, Turkey, 26 - 29 June 2018, pp.295-296
- XI. **Nose-to-brain delivery of farnesylthiosalicylic acid loaded hybrid nanoparticles in the treatment of glioblastoma**
Sekerdag E., LULE S., PEHLİVAN S., KARA A., OZTURK N., KAFFASHI A., VURAL İ., YAVUZ B. B. , OGUZ K. K. , SOYLEMEZOGLU F., et al.
23rd World Congress of Neurology (WCN), Kyoto, Japan, 16 - 21 September 2017, vol.381, pp.171-172
- XII. **IN VITRO PERMEATION STUDY FOR ORALLY DISINTEGRATING TABLETS CONTAINING MIRTAZAPINE**
yıldız s., AYTEKİN E., YAVUZ B., PEHLİVAN S., VURAL İ., Ünlü N.
2nd International Gazi Symposium Series, 11 - 13 October 2017
- XIII. **Pullulan Based Orally Disintegrating Films of Telmisartan**

Öztürk N., Pezik E., Kara A., Vural İ.

2nd International Gazi Symposium Series (GPSS 2017), Ankara, Turkey, 11 - 13 October 2017

- XIV. **DEVELOPMENT AND CHARACTERIZATION OF NOVEL CO-DELIVERY SYSTEM BASED ON DEXAMETHASONE SODIUM PHOSPHATE (DEX-NP) LOADED CHITOSAN WITH PLASMID DNA**
KARA A., ÖZTÜRK N., VURAL İ.

2nd INTERNATIONAL GPSS Gazi Pharma Symposium Series, Ankara, Turkey, 11 - 13 October 2017

- XV. **THE BIODISTRIBUTION OF FARNESYLTHIOSALICYLIC ACID INCORPORATED HYBRID NANOPARTICLES FOLLOWING INTRANASAL ADMINISTRATION IN RATS**
ŞEKERDAĞ E., LÜLE S., PEHLİVAN S., ÖZTÜRK N., KARA A., KAFFASHİ A., VURAL İ., IŞIKAY A. İ., YAVUZ B., KARLI OĞUZ H. K., et al.

2nd International Gazi Symposium Series, Ankara, Turkey, 11 - 13 October 2017

- XVI. **Orally Disintegrating Tablets of Telmisartan; Formulation Development and Evaluation**
Pezik E., Öztürk N., Vural İ.

2nd International Gazi Symposium Series (GPSS 2017), Ankara, Turkey, 11 - 13 October 2017

- XVII. **Design and In Vitro Evaluation of Bispecific Complexes and Drug Conjugates of Anticancer Peptide, LyP-1 in Human Breast Cancer**
DOĞAN S. S., Bhattarai P., GÜRSOY R. N., VURAL İ., Khaw B.

International Multidisciplinary Symposium on Drug Research and Development (DRD-2017), 5 - 07 October 2017

- XVIII. **Transferrine hedeflendirilmiş paklitaksel yüklü PLGA nanopartiküllerinin meme kanserindeki etkinliği**

TONBUL H., ŞAHİN A., ÖZTÜRK N., VURAL İ., KAYNAK M. S., ÇAPAN Y.

1. Anadolu Üniversitesi Eczacılık Fakültesi Sempozyumu (ANES), Turkey, 1 June - 02 January 2017

- XIX. **In vitro CACO-2 cell permeability studies of ritonavir nanosuspension formulation**
KARAKÜÇÜK A. E., ÖZTÜRK N., VURAL İ., TEKSİN Z. Ş., ÇELEBİ F. N.

6th FIP Pharmaceutical Sciences World Congress 2017, 21 - 24 May 2017

- XX. **Evaluation of Morphological and Physical Characteristics of Poly (2-Ethyl -2-Oxazoline)-co-Poly(Ethylenimine)-block-Poly(ε-Caprolactone) (PetOx-co-PEI-b-PCL) Polymeric Micelle as a Gene Delivery Agent**

KARA A., ÖZTÜRK N., ÖZKÖSE U., Bolat Z. B., Yılmaz Ö., TELCİ D., BOZKIR A., VURAL İ.

AAPS 2017, San Diego, United States Of America, 1 - 03 May 2017

- XXI. **EVALUATION OF MORPHOLOGICAL AND PHYSICAL CHARACTERISTICS OF Poly (2-Ethyl-2-Oxazoline)-co-Poly(Ethylenimine)-block-Poly(ε-Caprolactone) (PetOx-co-PEI-b-PCL) POLYMERIC MICELLE AS A GENE DELIVERY AGENT**

KARA A., ÖZTÜRK N., ÖZKÖSE U., BOLAT Z. B., YILMAZ Ö., TELCİ D., BOZKIR A., VURAL İ.

AAPS 2017 NATIONAL BIOTECHNOLOGY, San Diego, United States Of America, 1 - 03 May 2017

- XXII. **NOVEL POLYMERIC MICELLES BASED ON Poly-(2-Ethyl-2-Oxazoline)-co-Poly(ethylenimine)-block-Poly(ε-caprolactone) PETOx-co-PEI-b-PCL BLOCK COPOLYMER WITH VARIOUS HYDROLYSIS DEGREE TO EVALUATE THE EFFECT OF TRANSFECTION EFFICIENCY ON MCF-7 CELLS**

KARA A., ÖZTÜRK N., ESENDAĞLI G., BOLAT z. b., GÜLYÜZ s., TELCİ D., YILMAZ ö., BOZKIR A., VURAL İ.

AAPS 2017 NATIONAL BIOTECHNOLOGY CONGRESS, San Diego, United States Of America, 01 May 2107 - 03 May 2017

- XXIII. **Türk Farmakopesinde Majistraller**

VURAL İ.

Türk Farmakopesi Çalıştayı, Turkey, 26 - 28 January 2017

- XXIV. **Levofloxacin Dry Powder for Inhalation by Spray Drying Method**

AKDAĞ ÇAYLI Y., ŞAHİN S., Buttini F., Balducci A. G., Montanari S., VURAL İ., ÖNER L.

2016 AAPS Annual Meeting and Exposition, 13 - 17 November 2016

- XXV. **Development and Validation of an HPLC method for Simultaneous Determination of Ciprofloxacin Levofloxacin and N acetylcysteine**

AKDAĞ ÇAYLI Y., ŞAHİN S., VURAL İ., ÖNER L.

2016 AAPS Annual Meeting and Exposition, 13 - 17 November 2016

- XXVI. **Determination of Permeability of Ciprofloxacin Dry Powder Inhaler Formulations Across Calu 3 Cell Line**
AKDAĞ ÇAYLI Y., ŞAHİN S., VURAL İ., ÖNER L.
2016 AAPS Annual Meeting and Exposition, 13 - 17 November 2016
- XXVII. **Determination and Evaluation of Aerodynamic Parameters of Ciprofloxacin and Mucolytic Containing Dry Powder Inhalers**
AKDAĞ ÇAYLI Y., ŞAHİN S., BUTTINI F., BALDUCCI A. G. , MONTANARI S., VURAL İ., ÖNER L.
The Globalization of Pharmaceutics Education Network (GPEN) 2016, 9 - 12 November 2016
- XXVIII. **Determination of Itraconazole from Caco 2 Cells Using High Performance Liquid Chromatography**
Gökbulut E., VURAL İ., ÖZDEMİR A. N.
10th Aegean Analytical Chemistry Days, 29 September - 02 October 2016
- XXIX. **Dissolution profiles of fosinopril sodium orodispersible tablets and orodispersible films**
ŞAHİN G., ÖZTÜRK N., VURAL İ.
18th IPTS, 18 - 21 September 2016
- XXX. **Investigation of anti tumor effect of telmisartan loaded poly d l lactide nanoparticles on mcf 7 cells**
ÖZTÜRK N., KARA A., VURAL İ.
18th IPTS, 18 - 21 September 2016
- XXXI. **Micellar characteristics of poly 2 ethyl 2 oxazoline co poly ethylenimine block poly caprolactone petox co pei b pcl block copolymers of different hydrolysis degrees of PETox**
KARA A., ÖZTÜRK N., GÜLYÜZ S., ÖZKÖSE U. U. , VURAL İ., YILMAZ Ö., BOZKIR A.
18th IPTS, 18 - 21 September 2016
- XXXII. **In vitro evaluation of dexamethasone sodium phosphate dex np loaded chitosan nanoparticles as an antitumor agent on mcf 7 cell line**
KARA A., ÖZTÜRK N., VURAL İ.
18th IPTS, 18 - 21 September 2016
- XXXIII. **EVALUATION OF PERMEABILITY OF LEVOFLOXACIN CONTAINING DRY POWDER INHALER ACROSS CALU 3 CELL LINE**
AKDAĞ ÇAYLI Y., ŞAHİN S., VURAL İ., ÖNER L.
18th International Pharmaceutical Technology Symposium, 18 - 21 September 2016
- XXXIV. **Potential of Peptide Drug Conjugates for Targeted Breast Cancer Therapy**
DOĞAN S. S. , Bhattarai P., GÜRSOY R. N. , VURAL İ., Khaw B.
2016 AAPS National Biotechnology Conference, 16 - 18 May 2016
- XXXV. **Formulation and Characterization of Ciprofloxacin and Mucolytic Containing Dry Powder Inhaler Formulations**
AKDAĞ ÇAYLI Y., ŞAHİN S., VURAL İ., ÖNER L.
2015 AAPS Annual Meeting and Exposition, 25 - 29 October 2015
- XXXVI. **Formulation and Characterization of Levofloxacin and Mucolytic Containing Dry Powder Inhaler Formulations**
AKDAĞ ÇAYLI Y., ŞAHİN S., VURAL İ., ÖNER L.
3rd International TB-Meeting, 14 - 16 October 2015
- XXXVII. **Formulation and Characterization of Antibiotic and Mucolytic Containing Dry Powder Inhaler Formulations**
AKDAĞ ÇAYLI Y., ŞAHİN S., VURAL İ., ÖNER L.
1st European Conference on Pharmaceutics : Drug Delivery, 13 - 14 April 2015
- XXXVIII. **Formulation and In Vitro Evaluation of Furosemide Nanosuspensions**
GÜLSÜN İNAL T., sahand ebadi b., VURAL İ., ŞAHİN S.
1st European Conference on Pharmaceutics : Drug Delivery, Reims, France, 13 - 14 April 2015
- XXXIX. **Preparation and Evaluation of Furosemide Containing Orally Disintegrating Tablets by Direct Compression**
GÜLSÜN İNAL T., ÖZTÜRK N., KAYNAK M. S. , ŞAHİN S., VURAL İ.
AAPS Annual Meeting and Exposition, san diego, United States Of America, 2 - 06 November 2014

- XL. Effect of Precipitation Inhibitors on Supersaturation and Solubility of Furosemide**
ÖZTÜRK N., KARA A., GÜLSÜN İNAL T., PEHLİVAN S., VURAL İ., ŞAHİN S.
AAPS Annual Meeting and Exposition, san diego, United States Of America, 2 - 06 November 2014
- XLII. Development of Orally Disintegrating Tablets Containing Olmesartan Medoxomil and Amlodipine Besylate**
ÖZTÜRK N., GÜLSÜN İNAL T., KAYNAK M. S. , VURAL İ., ŞAHİN S.
AAPS Annual Meeting and Exposition, san diego, United States Of America, 2 - 06 November 2014
- XLIII. Effect of Milling Time on the Formulation Parameters of Nanosuspensions**
GÜLSÜN İNAL T., ÖZTÜRK N., PEHLİVAN S., ŞAHİN S., VURAL İ.
AAPS Annual Meeting and Exposition, San diego, United States Of America, 2 - 06 November 2014
- XLIV. Preparation and In vitro Evaluation of Furosemide Nanosuspensions for Enhancement of its Solubility and Permeability**
GÜLSÜN İNAL T., sahand ebadi b., GÜRİSOY R. N. , VURAL İ., ŞAHİN S.
17th International Pharmaceutical Technology Symposium, Antalya, Turkey, 8 - 10 September 2014
- XLV. Comparison of Furosemide Nanocrystals and Nanosuspensions in Terms of Solubility and Permeability**
ÖZTÜRK N., GÜLSÜN İNAL T., ŞAHİN S., VURAL İ.
17th International Pharmaceutical Technology Symposium, Antalya, Turkey, 8 - 10 September 2014
- XLVI. Formulation and Characterization of Ciprofloxacin Nanoparticles for Use in Dry Powder Inhalers**
AKDAĞ ÇAYLI Y., ŞAHİN S., VURAL İ., ÖNER L.
17th International Pharmaceutical Technology Symposium, 8 - 10 September 2014
- XLVII. Preparation and Characterization of Furosemide Nanosuspensions**
sahand ebadi b., GÜLSÜN İNAL T., GÜRİSOY R. N. , VURAL İ., ŞAHİN S.
AAPS Annual Meeting and Exposition, chicago, United States Of America, 14 - 18 October 2012
- XLVIII. Preparation of Furosemide Nanosuspensions by High Pressure Homogenization and Its In vivo Characterization**
GÜLSÜN İNAL T., sahand ebadi b., GÜRİSOY R. N. , VURAL İ., ŞAHİN S.
16th International Pharmaceutical Technology Symposium, Antalya, Turkey, 10 - 12 September 2012
- XLIX. Enhancement of Solubility of Nimesulide by Preparing Nanocrystal Formulation**
çisem b., GÜLSÜN İNAL T., VURAL İ., ŞAHİN S., ÖNER L.
Globalization of Pharmaceutics Education Network: Eighth Meeting, chapel hill, 10 - 12 November 2010
- L. Preparation and Characterization of Basic Fibroblast Growth Factor (bFGF)-Loaded Microparticulate Drug Delivery Systems,**
ÇETİN M., ÇAPAN Y., VURAL İ., GÜRİSOY R. N. , DALKARA T., Cuine A., HINCAL A.
2004 AAPS Annual Meeting and Exposition, Maryland, United States Of America, 31 October 2004
- L. Preservation of cardiocyte viability by immunoliposome-cell membrane sealing at 1, 2, 3, 4 and 5 days of hypoxia.**
Khaw B., Vural İ., Narula J., Haider N., Torchilin V.
23rd International Symposium on Controlled Release of Bioactive Materials, Kyoto, Japan, 7 - 10 July 1996, pp.617-618
- LI. Expression of antimyosin sFv gene in cardiocytes: Use of cytoskeleton-specific immunoliposomes for transfection.**
Khaw B., Vural İ., Torchilin V., Haider N., Narula J.
23rd International Symposium on Controlled Release of Bioactive Materials, Kyoto, Japan, 7 - 10 July 1996, pp.135-136

Supported Projects

PEHLİVAN S., VURAL İ., KAFFASHİ A., Project Supported by Higher Education Institutions, Farnesil Tiyosalisilik asit içeren nanopartikül formülasyonu, 2015 - 2019

VURAL İ., Project Supported by Higher Education Institutions, TELMISARTAN ICEREN PLA NANOPARTIKULLERİNİN İN VITRO KARAKTERİZASYONU VE DEĞERLENDİRİLMESİ, 2015 - 2016

VURAL İ., ÖZTÜRK N., Kara A., Project Supported by Higher Education Institutions, Lipofilik İlaçların Enkapsülasyonu İçin Aktif Hedeflendirilmiş Polimerik Nanotaşıyıcı Formülasyonlarının Optimizasyonu ve Hücre Kültürü Çalışmaları ile Değerlendirilmeleri, 2015 - 2016

VURAL İ., TÜBİTAK Project, Fosinopril sodyum içeren ağızda hızla dağılan dozaj formlarının geliştirilmesi ve karakterizasyonları, 2014 - 2016

Citations

Total Citations (WOS):1093

h-index (WOS):21